These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 35151637)
1. Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19. Finn A; Jindal A; Andrea SB; Selvaraj V; Dapaah-Afriyie K Am J Med Sci; 2022 May; 363(5):403-410. PubMed ID: 35151637 [TBL] [Abstract][Full Text] [Related]
2. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19. Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329 [TBL] [Abstract][Full Text] [Related]
3. Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study. Mozaffari E; Chandak A; Gottlieb RL; Chima-Melton C; Kalil AC; Sarda V; Der-Torossian C; Oppelt T; Berry M; Amin AN J Comp Eff Res; 2024 Apr; 13(4):e230131. PubMed ID: 38420658 [No Abstract] [Full Text] [Related]
4. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience. Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164 [TBL] [Abstract][Full Text] [Related]
5. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5. Molina KC; Webb BJ; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA BMC Infect Dis; 2024 Aug; 24(1):802. PubMed ID: 39118052 [TBL] [Abstract][Full Text] [Related]
6. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients. Platzer M; Totschnig D; Karolyi M; Clodi-Seitz T; Wenisch C; Zoufaly A Wien Klin Wochenschr; 2024 Aug; 136(15-16):458-464. PubMed ID: 38884783 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the safety profile and therapeutic efficacy of remdesivir in children with SARS-CoV-2 infection - a single-center, retrospective, cohort study. Kautsch K; Wiśniowska J; Friedman-Gruszczyńska J; Buda P Eur J Pediatr; 2024 Feb; 183(2):591-598. PubMed ID: 37864601 [TBL] [Abstract][Full Text] [Related]
8. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. Ali K; Azher T; Baqi M; Binnie A; Borgia S; Carrier FM; Cavayas YA; Chagnon N; Cheng MP; Conly J; Costiniuk C; Daley P; Daneman N; Douglas J; Downey C; Duan E; Duceppe E; Durand M; English S; Farjou G; Fera E; Fontela P; Fowler R; Fralick M; Geagea A; Grant J; Harrison LB; Havey T; Hoang H; Kelly LE; Keynan Y; Khwaja K; Klein G; Klein M; Kolan C; Kronfli N; Lamontagne F; Lau R; Fralick M; Lee TC; Lee N; Lim R; Longo S; Lostun A; MacIntyre E; Malhamé I; Mangof K; McGuinty M; Mergler S; Munan MP; Murthy S; O'Neil C; Ovakim D; Papenburg J; Parhar K; Parvathy SN; Patel C; Perez-Patrigeon S; Pinto R; Rajakumaran S; Rishu A; Roba-Oshin M; Rushton M; Saleem M; Salvadori M; Scherr K; Schwartz K; Semret M; Silverman M; Singh A; Sligl W; Smith S; Somayaji R; Tan DHS; Tobin S; Todd M; Tran TV; Tremblay A; Tsang J; Turgeon A; Vakil E; Weatherald J; Yansouni C; Zarychanski R; ; CMAJ; 2022 Feb; 194(7):E242-E251. PubMed ID: 35045989 [TBL] [Abstract][Full Text] [Related]
9. Disease-Specific Factors Associated with Readmissions or Mortality After Hospital Discharge in COVID-19 Patients: a Retrospective Cohort Study. Huang CW; Park JS; Song H; Khang VK; Yu AS; Nguyen HQ; Lee JS; Subject CC; Shen E J Gen Intern Med; 2022 Nov; 37(15):3973-3978. PubMed ID: 36104593 [TBL] [Abstract][Full Text] [Related]
10. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study. Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM; PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057 [TBL] [Abstract][Full Text] [Related]
11. Risk Factors for Therapeutic Intervention of Remdesivir in Mild to Moderate COVID-19-A Single-Center Retrospective Study of the COVID-19 Fourth Pandemic Period in Wakayama, Japan. Tamura S; Kaki T; Niwa M; Yamano Y; Kawai S; Yamashita Y; Tanaka H; Saito Y; Kajimoto Y; Koizumi Y; Yamaue H; Nakao N; Nojiri T; Hironishi M Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056426 [No Abstract] [Full Text] [Related]
12. Clinical Efficacy and Safety of Remdesivir among Hospitalised Adult Patients with RT PCR Confirmed COVID 19 Requiring ICU Care in Kalyana Karnataka. Waddankeri S; Hesarur SS; Hiremath SS; A S; Ar S; Raikod BP; Kinagi S; Biradar S; Belli B; Melkundi S; Singh G J Assoc Physicians India; 2021 Aug; 69(8):11-12. PubMed ID: 34472806 [TBL] [Abstract][Full Text] [Related]
13. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA; N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145 [TBL] [Abstract][Full Text] [Related]
14. Early remdesivir to prevent severe COVID-19 in recipients of solid organ transplant: a real-life study from Northern Italy. Colaneri M; Amarasinghe N; Rezzonico L; Pieri TC; Segalini E; Sambo M; Roda S; Meloni F; Gregorini M; Rampino T; Pelenghi S; Ricciardi A; Bruno R Int J Infect Dis; 2022 Aug; 121():157-160. PubMed ID: 35533831 [TBL] [Abstract][Full Text] [Related]
15. The effect of early versus late remdesivir treatment in hospitalized mild to moderate COVID-19 patients in the Omicron era: A retrospective study. Ryu BH; Lee JY; Lee SH Medicine (Baltimore); 2024 Jul; 103(29):e39035. PubMed ID: 39029053 [TBL] [Abstract][Full Text] [Related]
16. Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone. Wong CKH; Lau KTK; Au ICH; Xiong X; Chung MSH; Lau EHY; Cowling BJ Clin Infect Dis; 2022 Aug; 75(1):e499-e508. PubMed ID: 34420051 [TBL] [Abstract][Full Text] [Related]
17. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel. Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849 [TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. Piccicacco N; Zeitler K; Ing A; Montero J; Faughn J; Silbert S; Kim K J Antimicrob Chemother; 2022 Sep; 77(10):2693-2700. PubMed ID: 35913836 [TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital. Hidalgo-Tenorio C; García-Vallecillos C; Sequera-Arquelladas S; Medicine (Baltimore); 2021 Sep; 100(37):e27228. PubMed ID: 34664862 [TBL] [Abstract][Full Text] [Related]
20. Clinical Improvement, Outcomes, Antiviral Activity, and Costs Associated With Early Treatment With Remdesivir for Patients With Coronavirus Disease 2019 (COVID-19). Wong CKH; Lau KTK; Au ICH; Xiong X; Lau EHY; Cowling BJ Clin Infect Dis; 2022 Apr; 74(8):1450-1458. PubMed ID: 34265054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]